Brentuximab Vedotin Plus AVD: Limiting Toxicity in Limited-Stage Hodgkin Lymphoma
738 views · Published 18 June 2015 · 12:51 · Indexed 17 October 2026
Channel: American Society of Hematology · 2015 · Nonprofits & Activism
Jeremy Slade Abramson, MD, on findings from a phase II trial comparing brentuximab vedotin with or without AVD radiation therapy, which sought to reduce the adverse effects of radiation and bleomycin for patients with limited-stage Hodgkin lymphoma.
More from this channel
-
1:52
Ron Reagan Accepts ASH Award - Stem Cell Research
-
4:25
Sen. Jim Talent's Work on Sickle Cell Disease Legislation
-
3:56
ASH and the Reagans Support Stem Cell Research
-
5:42
The American Society of Hematology Celebrates its 50th Anniversary
-
5:57
David Nathan Receives 2011 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
5:17
James George Receives 2012 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
2:21
Congress: Protect NIH funding
-
2:21
Act Now: Tell Congress to Stop Further Cuts to Research Funding